3-(2-Azidoethyl)benzonitrile

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(2-Azidoethyl)benzonitrile
• 英文别名: 3-(2-azidoethyl)benzonitrile
• 化学式: C9H8N4
• 分子量: 172.19
• InChiKey: KCDPRJBFTCJLCY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  38.2
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] TRIS(1,2,3-TRIAZOL-4-YL)METHANE ORGANOMETALLIC COMPOUNDS AS CATALYSTS AND PROCESSES USING THEM.<br/>[FR] COMPOSÉS ORGANOMÉTALLIQUES DE TRIS(1,2,3-TRIAZOL-4-YL)MÉTHANE EN TANT QUE CATALYSEURS ET LEURS PROCÉDÉS D'UTILISATION
  申请人：INST CATALA D INVESTIGACIO QUIMICA ICIQ

  公开号：WO2011009934A1

  公开（公告）日：2011-01-27

  Compounds of formula (I) or theirs salts, where Y is a (C1-C4)alkyl biradical and n is 1 or 0; M is Cu, Ag, Au, V, Fe, Zn, Ni, Co, Mn, Ru, or Cr; R1 is a known ring system with 1 -2 rings, isolated or fused; each ring having 5-6 members independently selected from C, N, O, S, CH, CH2, and NH, the rings being saturated, partially unsaturated or aromatic, and optionally being substituted by at least one radical selected: halogen, nitro, cyano, (C1-C4)alkyl, halo-(C1-C4)alkyl, -O-(C1-C4)alkyl. -CO-(C1-C4)alkyl, - COO-(C1-C4)alkyl, -OC(O)-(C1-C4)alkyl, -C(O)NR4R5, -(C1-C4)alkyl-NR4R5, -S- (C1-C4)alkyl, -SO-(C1-C4)alkyl, -SO2-(C1-C4)alkyl, -NHSO2-(C1-C4)alkyl, -SO2- NR4R5, and -NR4R5; R2 is -OR3, wherein R3 is selected from the group consisting of hydrogen, benzyl, and an hydroxyl protective group, or a polymeric support, optionally including a linker; and R4 and R5 are independently H, (C1-C4)alkyl, (C2-C4)alkenyl, or (C2-C4)alkynyl, optionally substituted by at least one radical selected from halogen, nitro, cyano, and amino; are useful as catalyst, in particular, in a process for the preparation of substituted 1,2,3-triazoles.

  式(I)的化合物或其盐，其中Y是(C1-C4)烷基双基团，n为1或0；M为Cu、Ag、Au、V、Fe、Zn、Ni、Co、Mn、Ru或Cr；R1是已知的含有1-2个环的环系统，孤立或融合；每个环都有5-6个成员，独立地选自C、N、O、S、CH、CH2和NH，这些环是饱和的、部分不饱和的或芳香的，并且可以选择地被至少一个基团取代：卤素、硝基、氰基、(C1-C4)烷基、卤代(C1-C4)烷基、-O-(C1-C4)烷基、-CO-(C1-C4)烷基、-COO-(C1-C4)烷基、-OC(O)-(C1-C4)烷基、-C(O)NR4R5、-(C1-C4)烷基-NR4R5、-S-(C1-C4)烷基、-SO-(C1-C4)烷基、-SO2-(C1-C4)烷基、-NHSO2-(C1-C4)烷基、-SO2-NR4R5和-NR4R5；R2是-OR3，其中R3选自氢、苄基和一个羟基保护基，或者是一个聚合物支持体，可选地包括一个连接剂；R4和R5独立地是H、(C1-C4)烷基、(C2-C4)烯基或(C2-C4)炔基，可以选择地被至少一个基团取代，所述基团选自卤素、硝基、氰基和氨基；这些化合物在催化剂中很有用，特别是在制备取代1,2,3-三唑的过程中。
• CYCLOADDITION OF AZIDES AND ALKYNES
  申请人：Nolan Steven P.

  公开号：US20090069569A1

  公开（公告）日：2009-03-12

  This invention provides a process which comprises contacting, in a reaction zone, at least one organic azide, at least one alkyne, and at least one N-heterocyclic carbene copper compound in which the ligands are either (i) a halide and an N-heterocyclic carbene or (ii) two N-heterocyclic carbenes and a BF 4 − or PF 6 − anion, to form a 1,2,3-triazole in which at least the 1 and 4 positions each has a substituent. The N-heterocyclic carbene either an imidazol-2-ylidene in which the 1 and the 3 positions each has a substituent which has at least one carbon atom, or a 4,5-dihydro-imidazol-2-ylidene in which the 1 and the 3 positions each has a substituent which has at least one carbon atom.

  这项发明提供了一种方法，其中包括在反应区域中接触至少一种有机叠氮化合物、至少一种炔烃以及至少一种N-杂环卡宾铜化合物，其中配体可以是（i）一种卤素和一种N-杂环卡宾，或者（ii）两种N-杂环卡宾和一个BF4−或PF6−阴离子，以形成一种1,2,3-三唑，其中至少1和4位置各具有一个取代基。N-杂环卡宾可以是1,3位置各具有至少一个碳原子的咪唑-2-基卡宾，或者是1,3位置各具有至少一个碳原子的4,5-二氢咪唑-2-基卡宾。
• SRC KINASE INHIBITOR COMPOUNDS
  申请人：Merck & Co., Inc.

  公开号：EP1206265A1

  公开（公告）日：2002-05-22
• EP1206265A4
  申请人：——

  公开号：EP1206265A4

  公开（公告）日：2002-08-07
• [EN] SRC KINASE INHIBITOR COMPOUNDS<br/>[FR] COMPOSES INHIBITEURS DE LA SRC KINASE
  申请人：MERCK & CO INC

  公开号：WO2001000213A1

  公开（公告）日：2001-01-04

  Pyrimidine compounds (Formula I), or their pharmaceutically acceptable salts, hydrates, solvates, crystal forms and individual diastereomers, and pharmaceutical compositions including the same, which are inhibitors of tyrosine kinase enzymes, and as such are useful in the prophylaxis and treatment of protein tyrosine kinase-associated disorders, such as immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to play a role, such as cancer, angiogensis, atherosclerosis, graft rejection, rheumatoid arthritis and psoriasis.